Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Elevated p-eIF2α, and its proper sensing by the decameric eIF2B complex, are essential to balance translation. Knockdown or mutation of eIF2Bα and eIF2Bδ, two eIF2B subunits responsible for sensing ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

The central nervous system candidate is eIF2B activator ABBV-CLS-7262, in a multiple dose study to assess its safety and pharmacokinetics in patients with amyotrophic lateral sclerosis ...

both eIF2B agonists, in failing to slow disease progression in the study. There may be a silver lining, however, as two of them – pridopidine and CNM-Au8 – showed signs of activity on measure ...

DNL343 (small molecule eIF2B agonist) for the treatment of amyotrophic lateral sclerosis (ALS) In January 2025, Denali announced topline results that the primary endpoint was not met in the HEALEY ALS ...

Request permissions for this article.

H.C. Wainwright lowered the firm’s price target on Denali Therapeutics (DNLI) to $80 from $87 and keeps a Buy rating on the shares. The firm says the results of the primary analysis of the Phase ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...

CEL-SCI Corporation announced new data has been published from its prior Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in newly diagnosed, treatment naïve, resectable, locally ...